Breaking Finance News

Zacks Investment Research downgraded Aimmune Therapeutics Inc (NASDAQ:AIMT) to Sell in a report released today.

Zacks Investment Research has downgraded Aimmune Therapeutics Inc (NASDAQ:AIMT) to Sell in a report released on Monday March 20, 2017.

Yesterday Aimmune Therapeutics Inc (NASDAQ:AIMT) traded 0.80% higher at $22.61. The company’s 50-day moving average is $20.11 and its 200-day moving average is $19.52. The last closing price is up 15.82% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 261,580 shares of the stock traded hands, down from an average trading volume of 311,138

See Chart Below

Aimmune Therapeutics Inc (NASDAQ:AIMT)

Aimmune Therapeutics Inc has a 52 week low of $9.77 and a 52 week high of $27.31 The company’s market cap is currently $0.

General Information About Aimmune Therapeutics Inc (NASDAQ:AIMT)

Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. It has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. AR101 has been granted Fast-Track designation and Breakthrough Therapy designation. For patients in the up-dosing phase of the AR101 treatment regimen, AR101 would be provided in a series of color coded pharmaceutical grade capsules of various dose levels.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.